How high will this go?, page-71

Yes, the results are promising; 112 individuals over six months showed efficacy. If these findings are replicated in the Phase 3 trial (over one year), it should be enough to support a fast-track biologics license application, paving the way for commercialization. That’s why we’re here today.

That said, take the time to thoroughly review the results and understand the science. If you have a STEM background, anyone should be able at least a reasonable understanding of the science and maths shouldn’t be too difficult.

Looking ahead to April, we face a significant binary outcome. No one knows the result, but if it’s negative, expect substantial losses—potentially 85%, similar to PER (which failed on 2b, OPT is stronger position conducting P3) . However, if it succeeds, a $3 target wouldn’t be out of the question. Still a high risk / high reward play.